# Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy

> **NCT04159415** · PHASE2 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 16 (actual)

## Conditions studied

- Generalized Lipodystrophy

## Interventions

- **DRUG:** Placebo
- **DRUG:** Low-Dose REGN4461
- **DRUG:** High-dose REGN4461

## Key facts

- **NCT ID:** NCT04159415
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-07
- **Primary completion:** 2022-01-05
- **Final completion:** 2024-09-24
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04159415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04159415, "Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04159415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*